Kamada vs Phathom Pharmaceuticals
Kamada reported revenue of $180 million in fiscal 2025, about the same as Phathom Pharmaceuticals' $175 million in fiscal 2025. Kamada's revenue grew 12.1% in its latest year, and Phathom Pharmaceuticals' grew 216.9%. Kamada had an operating margin of 14.5%, against -91.4% at Phathom Pharmaceuticals. Free cash flow was $16 million at Kamada and −$167 million at Phathom Pharmaceuticals.
Side by side
| Kamada | Phathom Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $180M | $175M |
| Revenue growth | 12.1% | 216.9% |
| Revenue growth a year, last 5 years | 6.3% | — |
| Gross margin | 42.3% | 87.1% |
| Operating margin | 14.5% | −91.4% |
| Net margin | 11.2% | −126.3% |
| Free cash flow | $16M | −$167M |
| Free cash flow margin | 8.7% | −95.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $12M | $0M |
| Change in diluted share count | 0.9% | 15.4% |
| Last close | $7.83 | $5.08 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $1.7 million | — |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
KamadaPhathom Pharmaceuticals
Operating margin
Percent of revenue
KamadaPhathom Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
KamadaPhathom Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kamada and Phathom Pharmaceuticals pages.